Lexicon Pharma (LXRX) Misses Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
Revenue Growth %: -78.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $320 thousand versus the consensus estimate of $133.33 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
